Organogenesis (ORGO) Expected to Announce Earnings on Thursday

Organogenesis (NASDAQ:ORGO - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Thursday, May 8th. Analysts expect Organogenesis to post earnings of ($0.03) per share and revenue of $90.77 million for the quarter.

Organogenesis Trading Up 0.6 %

Organogenesis stock traded up $0.03 during trading hours on Tuesday, hitting $5.35. The stock had a trading volume of 128,101 shares, compared to its average volume of 1,136,113. The business's 50 day simple moving average is $4.67 and its 200-day simple moving average is $3.86. Organogenesis has a one year low of $2.21 and a one year high of $7.50. The stock has a market cap of $678.80 million, a price-to-earnings ratio of -89.42 and a beta of 1.85. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21.

Insider Activity at Organogenesis

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the transaction, the director now owns 166,879 shares in the company, valued at approximately $851,082.90. This trade represents a 13.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 36.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley lifted their target price on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.